Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

• Published in: NPJ breast cancer Vol. 9; no. 1; pp. 66 - 14
• Main Authors: Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11-08-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1059; 631/67/1347; Antibodies; Biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cell Biology; Chemotherapy; Epigenetics; FDA approval; Genes; Human Genetics; Medical research; Metastasis; Oncology; Protein expression; Proteins; Tumors
• ISSN: 2374-4677; 2374-4677
• DOI: 10.1038/s41523-023-00573-8

TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2, and downregulating transcription factor ZEB1 upregulates E-cad and TROP2, thus sensitizing cancers to TROP2 ADC sacituzumab govitecan (SG). Demethylating agent decitabine decreases DNA methyltransferase expression and TROP2 promoter methylation and subsequently increases TROP2 expression. Decitabine treatment as well as overexpression of TROP2 significantly enhance SG antitumor activity. Decitabine also increases SLFN11, a biomarker of topoisomerase 1 inhibitor (TOP1) sensitivity and is synergistic with SG which has a TOP1 payload, in TROP2-expressing SLFN11-low BC cells. In conclusion, TROP2 and SLFN11 expression can be epigenetically modulated and the combination of demethylating agent decitabine with TROP2 ADCs may represent a novel therapeutic approach for tumors with low TROP2 or SLFN11 expression.